APAC

DRUG2 trials

Sponsors

Aplagon Oy

Conditions

Chronic Limb-Threatening IschemiaChronic limb-threatening ischemia (CLTI)Peripheral Arterial Occlusive DiseasePeripheral arterial occlusive disease (PAOD)

Phase 2

A phase 2a open-label study to assess the safety, tolerability, and dosing regimen of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) in patients with peripheral arterial occlusive disease and chronic limb-threatening ischemia undergoing endovascular revascularization (HEALING -study)

Not yet recruitingCTIS2025-522390-11-00

Aplagon OyChronic limb-threatening ischemia (CLTI), Peripheral arterial occlusive disease (PAOD)

Target: 42Updated: 2025-09-15

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

RecruitingNCT07352800

Aplagon OyChronic Limb-Threatening Ischemia, Peripheral Arterial Occlusive Disease

Start: 2026-01-29End: 2027-06-30Target: 42Updated: 2026-02-03